Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs 1,319

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,319 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 18 of 28

  1. M19-753

    AbbVie Deutschland GmbH & Co. KG

    Myelofibrosis, Myeloproliferative Neoplasms

    phase 1 small molecule active

    1 trial

  2. M21-404

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    phase 1 other active

    1 trial

  3. M22-716

    AbbVie Deutschland GmbH & Co. KG

    Follicular lymphoma (FL), Chronic lymphocytic leukemia (CLL), Diffuse large b-cell lymphoma (DLBCL), B-cell malignancies

    phase 1 other active

    1 trial

  4. M23-385

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors

    phase 1 other active

    1 trial

  5. M24-291

    AbbVie Deutschland GmbH & Co. KG

    Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia

    phase 1 other active

    1 trial

  6. M24-427

    AbbVie Deutschland GmbH & Co. KG

    locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  7. M24-742

    AbbVie Deutschland GmbH & Co. KG

    Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  8. M24-893

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  9. M25-292

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  10. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  11. MC-1-50

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia, in Relapse

    phase 1 mab active

    1 trial

  12. MC-1-50

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 1 mab active

    1 trial

  13. MEN2312-01

    Stemline Therapeutics B.V.

    Advanced ER+/HER2- Breast Cancer

    phase 1 other active

    1 trial

  14. MK-4830-001

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  15. MK-8294-001

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

  16. MLN0264

    Takeda

    Advanced Gastrointestinal Carcinoma

    phase 1 small molecule terminated

    1 trial

  17. MLN1117

    Takeda

    Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  18. MLN2480

    Takeda

    Melanoma

    phase 1 small molecule completed

    1 trial

  19. MLN4924

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  20. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  21. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  23. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  24. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  25. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  26. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  27. MRx0518

    4D Molecular Therapeutics

    Pancreatic Cancer

    phase 1 small molecule terminated

    1 trial

  28. MRx0518 Capsules

    4D Molecular Therapeutics

    Melanoma

    phase 1 small molecule active

    1 trial

  29. MS100070_0087

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  30. MS201924_0001

    Merck Sharp and Dohme

    Metastatic or Locally Advanced Unresectable Solid Tumors

    phase 1 other active

    1 trial

  31. MS201924_0003

    Merck Sharp and Dohme

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  32. MS202359_0025

    Merck Sharp and Dohme

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

    phase 1 other active

    1 trial

  33. MS202650_0001

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  34. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  35. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  36. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  37. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  38. MTL-CEBPA

    Hospital Authority, Hong Kong

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  39. Mammaglobin-A DNA Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 mab active

    1 trial

  40. Marijuana via vape device

    BRIGHT MINDS BIOSCIENCES INC.

    Cigarette Smoking-Related Carcinoma

    phase 1 small molecule active

    1 trial

  41. Metabolically Armed CD19 CAR-T cells

    Anhui Provincial Hospital

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  42. Methylene Blue (50 mg/10ml)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Cancer

    phase 1 small molecule active

    1 trial

  43. Midazolam

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  44. Midazolam

    Takeda

    Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

    phase 1 small molecule completed

    1 trial

  45. Mifepristone and Eribulin in combination

    CORCEPT THERAPEUTICS INC

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  46. Minnelide™Capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  47. Mobocertinib

    Takeda

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  48. Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

    Disc Medicine

    Colorectal cancer, liver metastases

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,319 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.